What's Happening?
LEO Pharma, a global leader in medical dermatology, reported a 10% revenue growth at constant exchange rates in 2025, reaching DKK 13,499 million. The company also more than doubled its adjusted EBITDA margin to 16% from 7% in the previous year. This growth was driven by the launch of new products like Anzupgo® and Spevigo®, and strategic partnerships aimed at accelerating innovation. The company saw significant revenue increases in North America and continued expansion in Europe and the Rest of the World. LEO Pharma's dermatology portfolio, particularly its strategic brands, contributed significantly to this growth.
Why It's Important?
LEO Pharma's financial performance highlights the company's successful strategic transformation and its ability to innovate within
the dermatology sector. The growth in revenue and profitability underscores the effectiveness of its new product launches and strategic partnerships. This success not only strengthens LEO Pharma's market position but also enhances its capacity to invest in further innovation and global expansion. The company's focus on dermatology and its ability to deliver innovative treatments have significant implications for patient care and the broader healthcare industry.
What's Next?
For 2026, LEO Pharma expects revenue growth between 8-11% and further improvements in its adjusted EBITDA margin. The company plans to continue investing in innovation and expanding its global platform. The ongoing launch of Anzupgo® and the addition of Spevigo® are expected to drive future growth. LEO Pharma's strategic focus on innovation and partnerships will likely continue to play a crucial role in its growth strategy.
